We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dental Research Effort Aims to Stem Oral Cancer in India

By LabMedica International staff writers
Posted on 23 Sep 2015
Pioneering use of laser technology to advance better methods of tracking and treating oral cancers (OCs) is leading to the ability to noninvasively detect these cancers with a portable device.

Regular biopsies were standard practice to monitor precancerous mouth lesions before they may metastasized. More...
But often patients did not return after the first biopsy due to the pain. Petra Wilder-Smith, DDS, PhD, professor-in-residence and director of the dental program at the Beckman Laser Institute & Medical Clinic, University of California, Irvine (Irvine, CA, USA) and M.A. Kuriakose, chief of head and neck oncology at the Mazumdar-Shaw Cancer Center (Bangalore, India) have partnered in leading teams to develop and test a low-cost, portable screening device that field-workers in India can use to detect possible OC. The device is solar-powered, slightly larger than a shoebox, and can take laser images of oral lesions that will be sent via mobile phone to Mazumdar-Shaw and Beckman Laser Institute for assessment. The technology could enable people—many of whom rarely see dentists—to receive early-stage care and dramatically improve their outcomes.

“Petra is widely recognized for her visionary leadership in the pioneering use of optics and photonics technologies for improving oral health,” said Bruce Tromberg, director of the Beckman Laser Institute, “She has a special combination of abilities as a compassionate clinician with a unique understanding of patient needs, particularly in medically underserved communities.”

OCs are caused by a variety of factors, including tobacco and alcohol use, HPV infections, poor diets, and the chewing of betel quid, which is common in many parts of Asia. Most OC patients first see a doctor at late stages where survival rates are under 40%. In low-resource nations like India, which has the planet’s highest burden of OC (about 80,000 new cases annually), the situation is more acute, primarily due to lack of awareness and healthcare access. Data from the Million Death Study show that OC accounts for 35% of all cancer deaths among Indian men.

The study is in its first phase. Teams from Beckman and Mazumdar-Shaw have traveled India gauging mobile phone reception, and a prototype of the device has been tested on a small group of patients. They are gearing up for testing a larger cohort of subjects across India.

“We’re in the process of reviewing the data now to figure out where we draw the lines that determine whether a measurement signifies that the tissues are normal or precancerous or malignant,” said Dr. Wilder-Smith, “We’re really satisfied with the progress.” With another collaborator at the University of Arizona, she is creating a snap-on laser device for smartphones that can also perform lesion analysis in the field. The technology is in its experimental phase, and the researchers are seeking funding to support further development. “We are truly advancing methods to remotely use laser technology to diagnose tissues, which can help out both patients and oncologists,” she said.

Related Links:

Beckman Laser Institute & Medical Clinic, U California, Irvine
Mazumdar-Shaw Cancer Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Automated Immunoassay Analyzer
SuperFlex™
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.